No Longitudinal Association Between Hearing Loss and Alzheimer’s Disease Pathology - 07/01/26
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Highlights |
• | Baseline hearing loss (HL) was not linked to longitudinal changes in p-tau217. |
• | Baseline HL was not associated with incident amyloid PET positivity. |
• | HL progression did not predict PET outcomes. |
• | APOE4 carriership did not modify associations with Aβ PET. |
• | Baseline plasma biomarkers were also unrelated to longitudinal HL changes. |
Abstract |
Introduction |
Hearing loss (HL) is a potential risk factor for Alzheimer’s disease (AD), with animal studies suggesting a bidirectional relationship. This study examines whether HL links to changes in AD pathology and, whether AD biomarkers relate to subsequent HL progression.
Methods |
Baseline Aβ42/Aβ40 and p-tau217 were measured using single-molecule arrays in 474 participants of the Rotterdam Study (mean age=62.37) between 2010-2016. HL was defined as the better-ear’s pure-tone threshold average. After seven years, participants underwent amyloid PET; HL and p-tau217 were reassessed two years after PET.
Results |
Baseline HL was not associated with amyloid PET positivity, Aβ42/Aβ40, or longitudinally with p-tau217. Likewise, HL progression did not predict PET outcomes. APOE4 carriership did not modify associations with Aβ PET. Similarly, baseline plasma biomarkers were also unrelated to longitudinal HL changes.
Conclusion |
No bidirectional association was observed between HL and AD pathology, suggesting that HL may contribute to dementia through other pathways.
Le texte complet de cet article est disponible en PDF.KEYWORDS : Amyloid PET, plasma biomarkers, hearing loss, longitudinal, Alzheimer’s disease, risk factor
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.